DK3313816T3 - Metabolisk robuste analoger af cyp-eicosanoider til behandling af hjertesygdom - Google Patents
Metabolisk robuste analoger af cyp-eicosanoider til behandling af hjertesygdom Download PDFInfo
- Publication number
- DK3313816T3 DK3313816T3 DK16742303.7T DK16742303T DK3313816T3 DK 3313816 T3 DK3313816 T3 DK 3313816T3 DK 16742303 T DK16742303 T DK 16742303T DK 3313816 T3 DK3313816 T3 DK 3313816T3
- Authority
- DK
- Denmark
- Prior art keywords
- metabolicly
- eicosanoids
- cyp
- treatment
- heart disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562195645P | 2015-07-22 | 2015-07-22 | |
PCT/EP2016/067601 WO2017013265A1 (en) | 2015-07-22 | 2016-07-22 | Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3313816T3 true DK3313816T3 (da) | 2023-08-21 |
Family
ID=56550232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16742303.7T DK3313816T3 (da) | 2015-07-22 | 2016-07-22 | Metabolisk robuste analoger af cyp-eicosanoider til behandling af hjertesygdom |
Country Status (17)
Country | Link |
---|---|
US (1) | US11096910B2 (da) |
EP (1) | EP3313816B1 (da) |
JP (1) | JP6636133B2 (da) |
KR (1) | KR102071813B1 (da) |
CN (1) | CN108349880B (da) |
AU (1) | AU2016296923B2 (da) |
BR (1) | BR112018001164B1 (da) |
CA (1) | CA2992825C (da) |
DK (1) | DK3313816T3 (da) |
ES (1) | ES2952726T3 (da) |
HK (1) | HK1246771A1 (da) |
HU (1) | HUE062513T2 (da) |
IL (1) | IL256906B (da) |
MX (1) | MX2018000847A (da) |
RU (1) | RU2761438C2 (da) |
WO (1) | WO2017013265A1 (da) |
ZA (1) | ZA201800832B (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2208720A1 (en) * | 2009-01-13 | 2010-07-21 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Novel eicosanoid derivatives |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
KR102433731B1 (ko) * | 2016-04-01 | 2022-08-22 | 오메이코스 테라퓨틱스 게엠베하 | 혈관신생 및/또는 염증과 연관된 장애의 치료 또는 예방에서 사용하기 위한 cyp-에이코사노이드의 유사체 |
WO2022256097A1 (en) * | 2021-06-04 | 2022-12-08 | Cytometix, Inc. | Method of dosing a pain therapeutic |
WO2023094615A1 (en) * | 2021-11-26 | 2023-06-01 | Omeicos Therapeutics Gmbh | Synthetic eicosanoid analogues for the treatment and prevention of diseases associated with increased gdf15 plasma concentration |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095711A1 (en) * | 2006-08-31 | 2008-04-24 | Falck John R | Modulators of Pulmonary Hypertension |
RU2509071C2 (ru) * | 2006-11-01 | 2014-03-10 | Пронова Биофарма Норге Ас | Новые липидные соединения |
EP2208720A1 (en) * | 2009-01-13 | 2010-07-21 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Novel eicosanoid derivatives |
ES2593905T3 (es) * | 2011-04-06 | 2016-12-14 | The Medical College Of Wisconsin, Inc. | Análogos del ácido epoxieicosatrienoico y métodos de preparación y usos de los mismos |
EP3097076B1 (en) * | 2014-01-22 | 2019-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | Novel cyp-eicosanoid derivatives |
-
2016
- 2016-07-22 ES ES16742303T patent/ES2952726T3/es active Active
- 2016-07-22 HU HUE16742303A patent/HUE062513T2/hu unknown
- 2016-07-22 CN CN201680055242.8A patent/CN108349880B/zh active Active
- 2016-07-22 DK DK16742303.7T patent/DK3313816T3/da active
- 2016-07-22 JP JP2018507726A patent/JP6636133B2/ja active Active
- 2016-07-22 CA CA2992825A patent/CA2992825C/en active Active
- 2016-07-22 AU AU2016296923A patent/AU2016296923B2/en active Active
- 2016-07-22 MX MX2018000847A patent/MX2018000847A/es unknown
- 2016-07-22 RU RU2018101439A patent/RU2761438C2/ru active
- 2016-07-22 WO PCT/EP2016/067601 patent/WO2017013265A1/en active Application Filing
- 2016-07-22 KR KR1020187004984A patent/KR102071813B1/ko active IP Right Grant
- 2016-07-22 EP EP16742303.7A patent/EP3313816B1/en active Active
- 2016-07-22 US US15/746,246 patent/US11096910B2/en active Active
- 2016-07-22 BR BR112018001164-9A patent/BR112018001164B1/pt active IP Right Grant
-
2018
- 2018-01-14 IL IL256906A patent/IL256906B/en active IP Right Grant
- 2018-02-08 ZA ZA2018/00832A patent/ZA201800832B/en unknown
- 2018-05-09 HK HK18105994.5A patent/HK1246771A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3313816A1 (en) | 2018-05-02 |
KR20180066028A (ko) | 2018-06-18 |
BR112018001164B1 (pt) | 2023-11-21 |
CA2992825C (en) | 2021-05-04 |
RU2761438C2 (ru) | 2021-12-08 |
US20190133976A1 (en) | 2019-05-09 |
IL256906A (en) | 2018-03-29 |
HK1246771A1 (zh) | 2018-09-14 |
BR112018001164A2 (pt) | 2018-09-18 |
ZA201800832B (en) | 2019-07-31 |
AU2016296923A1 (en) | 2018-02-15 |
JP6636133B2 (ja) | 2020-01-29 |
EP3313816B1 (en) | 2023-05-24 |
IL256906B (en) | 2020-02-27 |
JP2018522937A (ja) | 2018-08-16 |
KR102071813B1 (ko) | 2020-01-30 |
WO2017013265A1 (en) | 2017-01-26 |
RU2018101439A (ru) | 2019-08-22 |
HUE062513T2 (hu) | 2023-11-28 |
US11096910B2 (en) | 2021-08-24 |
ES2952726T3 (es) | 2023-11-03 |
CA2992825A1 (en) | 2017-01-26 |
CN108349880B (zh) | 2021-03-09 |
RU2018101439A3 (da) | 2019-11-21 |
MX2018000847A (es) | 2018-06-22 |
AU2016296923B2 (en) | 2019-02-21 |
NZ739273A (en) | 2021-02-26 |
CN108349880A (zh) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3668562T3 (da) | Blodpumpe | |
DK3628344T3 (da) | Blodpumpe | |
DK3227262T3 (da) | Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling | |
DK3912673T3 (da) | Blodpumpe | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3795208T3 (da) | Blodpumpe | |
DK3069738T3 (da) | Blodpumpe | |
DK3069740T3 (da) | Blodpumpe | |
DK3474804T3 (da) | Medicinsk forbinding | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
GB201500314D0 (en) | Pharmaceutical formulations for the treatment of pulmonary arterial hypertension | |
DK3104854T3 (da) | Mast-celle-stabilisatorer til lungesygdomsbehandling | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3139855T3 (da) | Scanning af tandløse patienter | |
DK3258919T3 (da) | Næsepulverformulering til behandling af hypoglykæmi | |
DK3294283T3 (da) | Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens | |
DK3313816T3 (da) | Metabolisk robuste analoger af cyp-eicosanoider til behandling af hjertesygdom | |
DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
DE112017004905A5 (de) | Blutpumpe | |
DK3474803T3 (da) | Medicinsk forbinding | |
DK3373931T3 (da) | Heterocykliske forbindelser til behandling af sygdom | |
DK3203937T3 (da) | Subtalarledimplantat | |
BR112016015712A2 (pt) | método de tratamento de doenças hepáticas. | |
DK3325027T3 (da) | Medicinsk implantat | |
DK3484475T3 (da) | 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom |